



(51) International Patent Classification:

C07D 401/12 (2006.01) *A61K 31/4439* (2006.01)
C07D 207/26 (2006.01) *A61P 3/00* (2006.01)
A61K 31/402 (2006.01)

(21) International Application Number:

PCT/EP2015/057413

(22) International Filing Date:

2 April 2015 (02.04.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

14305491.4 4 April 2014 (04.04.2014) EP

(71) Applicant: **SANOFI** [FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).

(72) Inventors: **SCHWINK, Lothar**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BUNING, Christian**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **GLOMBIK, Heiner**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **GOSSEL, Matthias**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **KADEREIT, Dieter**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **HALLAND, Nis**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **LOHMANN, Matthias**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **PÖVERLEIN, Christoph**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **RITTER, Kurt**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) Agent: **GRIEBEL, Nicole**; Michalski - Hüttermann & Partner Patentanwälte mbB, Speditionstraße 21, 40221 Düsseldorf (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

(57) Abstract: The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

